Diagnosis and Treatment of Malignant Lymphomas in the Elderly

  • Jagadeesh C. Gaddipati
  • Michael L. Friedland
  • Zalmen Arlin
Part of the Contemporary Geriatric Medicine book series (COGM, volume 2)


The process of aging is associated with structural and functional changes occurring in the living organism and often expressed in gradual deterioration and decline in performance. These impairments result in changes in host resistance and are perhaps the major factors in the emergence of neoplasia in those elderly who have survived the ravages of vascular diseases, accidents, and infection. The hematologic neoplasms are generally diseases of higher incidence with advancing age. These disorders are uncommon under the age of 40; although they do not represent a national health hazard, they are not rare. Malignant lymphomas have an incidence of 82 cases per million. The occurrence of the lymphomas and the ability of the host to deal with them as well as responses to therapy are all modified by advanced age and will be discussed in this chapter.


Multiple Myeloma Malignant Lymphoma Mycosis Fungoides Autoimmune Thrombocytopenic Purpura Electron Beam Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mackay, R. R., 1972, Aging and immunologic function in man, Gerontologia 18: 285.PubMedCrossRefGoogle Scholar
  2. 2.
    Diaz-Jouanen, E., Strickland, R., and Williams, S. R., 1975, Studies of human lymphocytes in the new born and the aged, Am. J. Med. 58: 620.CrossRefGoogle Scholar
  3. 3.
    Young, R. C., Corder, M. P., and Haynes, H. A., 1972, Delayed hypersensitivity in Hodgkin’s disease: A study of 103 patients, Am. J. Med. 52: 63–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Jones, S. E., Griffith, K., and Dombrowski, P., 1977, Immunodeficiency in patients with non-Hodgkin’s lymphoma, Blood 49: 335–344.PubMedGoogle Scholar
  5. 5.
    Moore, D. F., Migliore, P. H., and Shullenberger, C. C., 1970, Moncoclonal macroglobulinemia in malignant lymphoma, Ann. Intern. Med. 72: 43.PubMedGoogle Scholar
  6. 6.
    MacMahon, B., 1957, Epidemiologic evidence on the nature of Hodgkin’s disease, Cancer 10: 1045–1054.PubMedCrossRefGoogle Scholar
  7. 7.
    Greco, R. S., Acheson, R. S., and Foote, F. M., 1974, Hodgkin’s disease in Connecticut from 1935 to 1962: The bimodal incidence curve in the general population and survival in untreated patients, Arch. Intern. Med. 134: 1039–1042.Google Scholar
  8. 8.
    Newell, G. R., Cole, S. R., Miettinen, O. S., and MacMahon, B., 1970, Age differences in the histology of Hodgkin’s disease, J. Nat. Cancer, Inst. 45: 311–317.Google Scholar
  9. 9.
    Lokich, J. J., Pinkus, G. S., and Moloney, W. C., 1974, Hodgkin’s disease in the elderly, Oncology 29: 484–500.PubMedCrossRefGoogle Scholar
  10. 10.
    Goodman, R. L., Piro, A. J., and Hellman, S., 1976, Can pelvic irradiation be omitted in patients with pathologic stages IA and IIA Hodgkin’s disease? Cancer 37: 2834–2839.PubMedCrossRefGoogle Scholar
  11. 11.
    Hellman, S., 1979, An evaluation of total nodal irradiation as treatment for stage IIIA Hodgkin’s disease, Cancer 43: 1255–1261.PubMedCrossRefGoogle Scholar
  12. 12.
    DeVita, V. T., Hubbard, S. M., Moxley, J. H., Ill, 1983, The Cure of Hodgkin’s Disease with Drugs, yearbook Medical Publishers, Inc., Chicago, pp. 277–301.Google Scholar
  13. 13.
    Bonadonna, G., Santoro, A., Bonfante, V., and Valagussa, P., 1982, Cyclic delivery of MOOP and ABVD combinations in stage IV Hodgkin’s disease: Rationale, background studies and recent results, Cancer Treat Rep 66: 881–887.PubMedGoogle Scholar
  14. 14.
    Penn, I., 1975, The incidence of malignancies in transplant recipients, Transplant Proc 7: 323–326.PubMedGoogle Scholar
  15. 15.
    Jones, S. E., Fuks, Z., Bull, M., Kadin, M. E., Dorfman, R. F., Kaplan, H. S., Rosenberg, S. A., and Kim, H., 1973, Non-Hodgkin’s lymphomas IV. Clinico pathological correlation in 405 cases Cancer 31: 806–823.Google Scholar
  16. 16.
    Jones, S. E., Fuks, A., Kaplan, H. S., and Rosenberg, S. A., 1973, Non-Hodgkin’s lymphomas. V. Results of radiotherapy, Cancer 32: 682–691.PubMedCrossRefGoogle Scholar
  17. 17.
    Berard, C. W, Greene, M. H., Jaffe, E. S, Magrath, I, and Ziegler, J., 1981, NIH conference. A multi disciplinary approach to non-Hodgkin’s lymphomas, Ann. Intern. Med. 94 (2): 218–235.PubMedGoogle Scholar
  18. 18.
    Portlock, C. S., and Rosenberg, S. A., 1979, No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favourable histologic types, Ann. Intern. Med. 90: 10–13.PubMedGoogle Scholar
  19. 19.
    Canellos, G. P., Skarin, A. T., and Rosenthal, D. S., 1981, Methotrexate as a single agent in combination chemotherapy for the treatment of non-Hodgkin’s lymphomas of unfavourable histology, Cancer Treat Rep. 65 (Suppl. 1): 125–129.PubMedGoogle Scholar
  20. 20.
    Armitage, J. O., and Potter, J. F., 1984, Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age, J. Am. Geriatr. Soc. 32: 269–273.PubMedGoogle Scholar
  21. 21.
    Case, D. C., Jr., Lee, B. J., II, and Clarkson, B. D., 1977, Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, BCNU: M2 protocol, Am. J. Med. 63: 897–903.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Jagadeesh C. Gaddipati
    • 1
    • 2
  • Michael L. Friedland
    • 1
    • 2
  • Zalmen Arlin
    • 1
    • 2
  1. 1.Division of Neoplastic Diseases, Department of MedicineNew York Medical CollegeValhallaUSA
  2. 2.Westchester County Medical CenterValhallaUSA

Personalised recommendations